Ireland’s medicines regulator is assessing the possible implications for Ireland after the drugmaker Astellas was accused of “shocking” breaches of guidelines that “raised serious concerns with regard to patient safety” in Britain.
In a statement to this newspaper last week, the Health Products Regulatory Authority (HPRA) said it was concerned and was “following up with Astellas as regards any possible implications for the advertising and promotion of the company’s...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Team Pass
Get a Business Account for you and your team